SCHEMBL4471820

SCHEMBL4471820

O=Cc1ccc(Br)cc1N1CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A3 P47895 5/20 0.45
MAPT P10636 7/20 0.44
NPC1 O15118 2/20 0.43
HTT P42858 2/20 0.43
RAB9A P51151 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
GAA P10253 1/20 0.43
ERN1 O75460 1/20 0.42
KDM4E B2RXH2 1/20 0.41
TRIM24 O15164 1/20 0.38
TRIM33 Q9UPN9 1/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4528462 0.98 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2ALDH1A3MAPTNPC1
SCHEMBL6103152 0.86 ALDH1A3 (0.49) ALDH1A1SMN1; SMN2ALDH1A3MAPTNPC1
SCHEMBL6104382 0.86 ALDH1A3 (0.49) ALDH1A1SMN1; SMN2ALDH1A3MAPTNPC1
SCHEMBL6103643 0.86 ALDH1A3 (0.49) ALDH1A1SMN1; SMN2ALDH1A3MAPTNPC1
SCHEMBL6104298 0.84 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2ALDH1A3MAPTNPC1
SCHEMBL1277259 0.83 PRKDC (0.51) ALDH1A1SMN1; SMN2ALDH1A3MAPTHTT
SCHEMBL3690553 0.83 HTT (0.48) ALDH1A1SMN1; SMN2MAPTHTTMEN1
SCHEMBL25692327 0.82 ERN1 (0.39) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL30642982 0.82 ERN1 (0.39) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL26618064 0.81 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2MAPTNPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312499-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2023-10-05 US disclosed
US-20230312499-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2023-10-05 US disclosed
CN-107982266-B Carbamate compounds and methods of making and using the same H.隆德贝克有限公司 2021-07-30 CN disclosed
EP-3698782-A1 CARBAMATE COMPOUNDS FOR USE IN THERAPY Lundbeck La Jolla Research Center, Inc. (US) 2020-08-26 EP disclosed
EP-2800565-B1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME LUNDBECK LA JOLLA RESEARCH CENTER INC (US) 2020-03-25 EP disclosed
US-20180208568-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2018-07-26 US disclosed
EP-3326627-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME Abide Therapeutics, Inc. (US) 2018-05-30 EP disclosed
CN-107982266-A Carbamate compounds and its preparation and application 阿比德治疗公司 2018-05-04 CN disclosed
US-9957242-B2 Carbamate compounds and methods of making and using same THE SCRIPPS RESEARCH INSTITUTE (US) 2018-05-01 US disclosed
CN-104159581-B Carbamate compounds and methods of making and using the same 阿比德治疗公司 2017-09-01 CN disclosed
EP-2828253-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME Abide Therapeutics, Inc. (US) 2015-01-28 EP disclosed
WO-2013142307-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME ABIDE THERAPEUTICS (US) 2013-09-26 WO disclosed
WO-2013142307-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME ABIDE THERAPEUTICS (US) 2013-09-26 WO disclosed
US-7629366-B2 Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2009-12-08 US disclosed
CN-1802355-A Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO (JP) 2006-07-12 CN disclosed
US-20060100252-A1 Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2006-05-11 US disclosed
US-7037938-B2 Aminoalcohol derivatives ASTELLAS PHARMA INC. (JP) 2006-05-02 US disclosed
EP-1546086-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-29 EP disclosed
US-20040006143-A1 For therapy of urinary incontinence FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-08 US disclosed
WO-2004002939-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180208568-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME ABHD6, ABHD16A, NCEH1 ALDH1A1 1712/4885SMN1; SMN2 1553/4885ALDH1A3 1213/4885
US-20060100252-A1 Aminoalcohol derivatives H1-0, CHRM2, CHRM1 ALDH1A1 675/4885SMN1; SMN2 3190/4885ALDH1A3 1572/4885
US-20230312499-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME ABHD6, ABHD16A, RABL6 ALDH1A1 2487/4885SMN1; SMN2 2374/4885ALDH1A3 1192/4885
US-20040006143-A1 For therapy of urinary incontinence H1-0, HRH2, H1-2 ALDH1A1 1320/4885SMN1; SMN2 1849/4885ALDH1A3 1412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.